Precursor lymphoblastic lymphoma/leukemia
MONDO:0003538A neoplasm of immature malignant lymphocytes (lymphoblasts) committed to the B-cell or T-cell lineage. Neoplasms involving the bone marrow and the peripheral blood are called precursor lymphoblastic leukemias or acute lymphoblastic leukemias. Neoplasms involving primarily lymph nodes or extranodal sites are called lymphoblastic lymphomas. -- 2003
Also known as: precursor lymphoblastic leukemia/lymphoma, precursor lymphoblastic lymphoma/leukemia, precursor lymphoid neoplasm
3155 clinical trials for this condition and its sub-types, 12 tagged with Precursor lymphoblastic lymphoma/leukemia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Precursor lymphoblastic lymphoma/leukemia
-
Acute lymphoblastic leukemia 507 trials · 1,317 incl. sub-types
12 sub-types
- B-cell chronic lymphocytic leukemia 509 trials · 538 incl. sub-types Sub-types →
- B-cell acute lymphoblastic leukemia 244 trials · 258 incl. sub-types Sub-types →
- Childhood acute lymphoblastic leukemia 96 trials · 136 incl. sub-types Sub-types →
- Precursor B-cell acute lymphoblastic leukemia 66 trials · 111 incl. sub-types Sub-types →
- T-cell acute lymphoblastic leukemia 75 trials · 104 incl. sub-types Sub-types →
- Acute biphenotypic leukemia 88 trials · 91 incl. sub-types Sub-types →
- Adult acute lymphoblastic leukemia 43 trials · 54 incl. sub-types Sub-types →
- Prolymphocytic leukemia 20 trials · 38 incl. sub-types Sub-types →
- Plasma cell leukemia 32 trials
- Lymphoblastic leukemia, acute, with lymphomatous features 7 trials
- Precursor T-cell acute lymphoblastic leukemia 4 trials
- Null-cell leukemia 0 trials
-
Lymphoblastic lymphoma 78 trials · 104 incl. sub-types
2 sub-types
- T-lymphoblastic lymphoma 32 trials
- T-cell childhood lymphoblastic lymphoma 4 trials
-
T lymphoblastic leukemia/lymphoma 18 trials · 100 incl. sub-types
5 sub-types
- T-lymphoblastic lymphoma 32 trials
- Refractory precursor T-lymphoblastic lymphoma/leukemia 31 trials
- T-cell prolymphocytic leukemia 17 trials
- Childhood precursor T-lymphoblastic lymphoma/leukemia 0 trials · 13 incl. sub-types Sub-types →
- Aggressive NK-cell leukemia 11 trials
-
B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormality 0 trials · 59 incl. sub-types
6 sub-types
- B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) 51 trials
- B-lymphoblastic leukemia/lymphoma with t(v;11q23.3) 8 trials
- B-lymphoblastic leukemia/lymphoma with hypodiploidy 3 trials
- B-lymphoblastic leukemia/lymphoma with hyperdiploidy 0 trials
- B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1) 0 trials
- B-lymphoblastic leukemia/lymphoma with t(5;14)(q31.1;q32.3) 0 trials
Most studied deeper sub-types
-
Experimental CART123 therapy targets tough blood cancers in early trial
Disease control OngoingThis early-phase trial tests a personalized cell therapy called CART123 for people with certain blood cancers (like AML or MDS) that have not responded to standard treatments. Each patient's own immune cells are modified in a lab to recognize and attack cancer cells. The main goa…
Early phase 1 • Sponsor: Institute of Hematology and Blood Transfusion, Czech Republic • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
One-Time infusion aims to build cancer killers inside the body
Disease control OngoingThis early study tests a new gene therapy called INT2104 in 10 adults with B-cell cancers that have come back or not responded to treatment. The therapy is given as a single IV infusion and works by instructing the body to create its own cancer-fighting T cells and natural killer…
Phase 1 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a smart patch predict dangerous immune reactions in cancer treatment?
Knowledge-focused By invitation onlyThis study tests whether a wearable patch called TempTraq can detect fevers earlier than standard temperature checks in cancer patients receiving immunotherapy. The goal is to see if continuous monitoring reduces the risk of severe cytokine release syndrome (CRS), a serious side …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC